FDA drug approval workshop
This article was originally published in The Tan Sheet
Executive Summary
A public workshop for businesses marketing unapproved OTC and prescription drugs will be hosted by FDA Jan. 9 in Rockville, Md., the agency announces in the Nov. 1 Federal Register. FDA will provide clarification and direction to companies on how to seek drug approval, and topics slated for the meeting include NDAs, ANDAs, OTC monographs, application processes, user fees and market exclusivity. Participants must register for the meeting by Nov. 15, which is also the deadline to propose discussion topics for the workshop. FDA says it is convening the meeting because many companies sought clarification following the June 2006 publication of the agency's Marketed Unapproved Drugs-Compliance Policy Guide (1"The Tan Sheet" June 12, 2006, p. 3)...
You may also be interested in...
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.